Market revenue in 2022 | USD 281.9 million |
Market revenue in 2030 | USD 1,289.6 million |
Growth rate | 20.9% (CAGR from 2022 to 2030) |
Largest segment | Gene panel, ldt & others |
Fastest growing segment | Liquid Biopsy |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Liquid Biopsy, Gene Panel, LDT & Others |
Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multi cancer early detection market will help companies and investors design strategic landscapes.
Gene panel, ldt & others was the largest segment with a revenue share of 98.12% in 2022. Horizon Databook has segmented the North America multi cancer early detection market based on liquid biopsy, gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
North America is expected to be the fastest-growing region in the global MCED market, owing to high cancer prevalence, rapid technological advancements, and growing number of supportive government initiatives. It is led by the U.S. owing to major investments and the local presence of several biotechnology companies developing novel MCED tests.
Various organizations, such as the American Society of Clinical Oncology (ASCO), support the implementation of early cancer detection products, which is likely to boost revenue in this market. The market is expected to grow during the forecast period owing to intense competition between biotechnology companies and increasing investments by governments in healthcare institutes to develop sophisticated tests.
Oncologists are more inclined to liquid biopsy tests, as they are minimally invasive and have fewer complications. However, high cost of tests, low awareness, and lack of proper testing standards may pose a threat to market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America multi cancer early detection market , including forecasts for subscribers. This continent databook contains high-level insights into North America multi cancer early detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account